Therefore, there is a strong unmet need to further improve the clinical efficacy of the immune checkpoint inhibitors, and our study highlighted TGFβ as a promising target to overcome the immune escape mechanisms involved in the T-cell excluded tumours. Here, TGFB1 is linked to neoplasm.